Medtronic touts five-year VenaSeal study data

April 17, 2019 By Fink Densford Leave a Comment

Medtronic (NYSE:MDT) today released five-year results from the VeClose extension study of its VenaSeal closure system, touting durable and consistent long-term outcomes with the system when used to treat patients with chronic venous disease.

The VenaSeal device is a medical adhesive designed to close off the great saphenous vein for treating chronic venous insufficiency and varicose veins.

Results from the trial were presented at the 2019 Charing Cross Symposium in London by Dr. Nick Morrison of the Mesa, Ariz.-based Center for Vein Restoration.

Fridley, Minn.-based Medtronic said that the VeClose extension study was a follow-on study looking to evaluate long-term outcomes at five years post-treatment with the VenaSeal system, which included data from 47 randomized subjects and nine roll-in subjects.

Results from the trial indicate a 94.6% rate of closure of the great saphenous vein at five years, Medtronic said.

“The five-year data support the safety, effectiveness, and quality of life-enhancing capability of both VenaSeal and ClosureFast in treating patients with chronic venous disease. Furthermore, the data demonstrate long-term, strong, and consistent outcomes. The industry will benefit from long-term data like this so that physicians and patients can be confident in their treatment choice,” Dr. Morrison said in a prepared statement.

In the original study, patients were randomized to treatment with either the VenaSeal system or with Medtronic’s ClosureFast radiofrequency ablation device.

Using a Kaplan-Meier analysis of randomized subjects to analyze success over the life of the five-year extended study, investigators reported a 91.4% vein closure estimate for the VenaSeal versus an 85.2% for the RFA.

Patient improvement in the trial was judged based on assessments including the Venous Clinical Severity Score (VCSS), the Aberdeen Varicose Vein Questionnaire (AVVQ) and the EQ-5D. The VCSS is a clinical venous disease assessment, while the other two assessments provide quality of life outcomes.

Five-year data from the trial indicates that subjects sustained or maintained quality of life improvements after treatment with both the VenaSeal or RFA.

“The Medtronic commitment to long-term clinical evidence and improving patient outcomes is underscored by the release of this five-year VeClose extension study data. VenaSeal has already been used in more than 100,000 procedures and that number is growing daily. We want to continue to expand minimally invasive innovation to improve the quality of life for all patients with venous disease,” endovenous biz GM Sandra Lesenfants said in a press release.

Medtronic won FDA premarket approval for the device, which was originally developed by Covidien, in February of 2015.

These ‘smart’ bandages could heal chronic woulds
UConn biomedical engineers are touting a wirelessly controlled “smart” bandage and corresponding platform for delivering medications to chronic, non-healing wounds. UConn’s School of Dental Medicine, School of Medicine and School of Engineering comprise the biomedical engineering department, which contributed to developing the smart bandage. Ali Tamayol, an associate professor at UConn, led the development of… […]
How to cook up a successful medtech company
New medical device companies need much more than money to get their businesses started. A medtech-specific accelerator can help with seed funding and positioning for a Series A round. Shai Policker, MEDX Xelerator As we dive into 2020, the medtech sector will continue to offer tremendous opportunity for innovators and investors alike, with growth projected… […]
Could this patch help mend a broken heart?
Researchers in Ireland have developed a prototype patch that they say does the same job as crucial aspects of heart tissue. The patch was designed to withstand the mechanical demands of heart tissue and mimic the electrical signaling properties that allow the heart to pump blood throughout the body. The researchers believe it brings medtech… […]
Black History Month: This inventor laid the foundation for today’s pacemakers
Most people in medtech know of Earl Bakken’s contributions to pacemakers and cardiac rhythm devices, but without Otis Boykin, pacemakers wouldn’t have the pacing technology they do today. Boykin, an African-American inventor and engineer, had a special interest in resistors. His mother died from heart failure when he was 1 year old. Thirty-one years later,… […]
Could this 3D bioink printer speed wound healing?
The University of Toronto is touting a new handheld 3D printer that can deposit sheets of skin to cover burn wounds and accelerate the healing process. A study, led by Richard Cheng under the supervision of Axel Guenther, published in Biofabrication revealed that the 3D printer completed successful in-vivo trials on full-thickness wounds, according to a report… […]
8 types of FDA-approved devices that treat the heart
Just starting to learn about all of the medical devices out there for treating cardiovascular diseases? The U.S. FDA has a good, basic roundup on its website of the most common types of cardiovascular devices it regulates. Here’s the list, along with the FDA’s descriptions: 1. Automated external defibrillators (AEDs) “Portable and automatic, these devices… […]
Medtronic seeks to boost surgical robotics play with Digital Surgery acquisition
Medtronic (NYSE:MDT) announced today that it has acquired Digital Surgery (London), a privately-held pioneer in surgical artificial intelligence, data and analytics, and digital education and training. Financial terms of the deal were not disclosed. Medtronic said the purchase will strengthen its robot-assisted surgical platform and its broader portfolio. The medical device giant is making a big play… […]
Solvay expands advanced materials offerings in the medtech space
Solvay, a supplier of advanced materials and specialty chemicals, announced a pair of advances that it hopes will help it expand its healthcare business. Speaking yesterday at Solvay’s booth (#2414) at MD&M West, the company’s healthcare sales development manager Rose Catherin said the new materials will help improve the performance of specialty surgical devices including… […]
11 states ask EPA to crack down on ethylene oxide emissions
Eleven state attorneys general are urging the U.S. Environmental Protection Agency to impose stricter regulations over commercial operations that emit ethylene oxide (EtO), a widely used medical device sterilant gas. The EPA, which considers EtO a carcinogen, has been fielding comments on it in light of public outcry over emissions from medtech sterilization plants during… […]
Is it possible to ‘knit’ replacement blood vessels?
A new way to replace a patient’s damaged blood vessels may be on its way, as researchers in France are figuring out a way to “knit” new vessels with a collagen-based extracellular matrix. Inserm researcher Nicolas L’Heureux and his colleagues at Inserm/Université de Bordeaux’s tissue bioengineering unit published a study in Acta Biomaterialia to outline… […]
Applied Plastics has a new website, online store
Applied Plastics (Norwood, Mass.) — maker of PTFE-coated products for advanced catheter systems — announced today that it is rebranding to improve its customer interface and support continued growth. The rebranding includes a new website, online store and refreshed brand identity. The company this week is showing off the new look and its online PTFE… […]